MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keae392

Медицинская библиотека · Rheumatology (Oxford, England) · 2024

Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis.

Papadopoulou Charalampia, Martin Neil, Rafiq Nadia, McCann Liza, Varner Giulia, Nott Kerstin, Compeyrot-Lacassagne Sandrine, Leandro Maria, Foley Charlene, Warrier Kishore, Green Nathan, Wan Mandy, Dehbi Hakim-Moulay, Whitehead John, Eleftheriou Despina, Brogan Paul

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To elicit and quantify expert opinion concerning the relative merits of two treatments for a rare inflammatory disease: JDM. The formal expression of expert opinion reported in this article will be used in a Bayesian analysis of a forthcoming randomized controlled trial known as BARJDM (baricitinib for JDM).

METHODS

A Bayesian prior elicitation meeting was convened, following a previously described methodological template. Opinion was sought on the probability that a patient in the BARJDM trial would achieve clinically inactive disease, off glucocorticoids (GC) within a 12-month period with either MTX (standard of care); or baricitinib (a Janus kinase inhibitor, JAKi), with GC schedules identical in both arms of the trial. Experts' views were discussed and refined following presentation and further discussion of summated published data regarding efficacy of MTX or JAKi for JDM.

RESULTS

Ten UK paediatric rheumatology consultants (including one adolescent paediatric rheumatologist) participated in the elicitation meeting. All had expertise in JDM, leading active National Health Service clinics for this disease. Consensus expert prior opinion was that the most likely probability of clinically inactive disease off GC within 12 months was 0.55 on baricitinib and 0.23 on MTX, with a greater degree of uncertainty for baricitinib.

CONCLUSION

Experts currently think that baricitinib is superior to MTX for the treatment of JDM, although there is uncertainty around this. BARJDM will therefore integrate randomized trial data with this expert prior opinion to derive a posterior distribution for the relative efficacy of baricitinib compared with MTX.

Для цитирования: Papadopoulou Charalampia, Martin Neil, Rafiq Nadia, McCann Liza, Varner Giulia, Nott Kerstin, Compeyrot-Lacassagne Sandrine, Leandro Maria, Foley Charlene, Warrier Kishore, Green Nathan, Wan Mandy, Dehbi Hakim-Moulay, Whitehead John, Eleftheriou Despina, Brogan Paul. Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis.. Rheumatology (Oxford, England). 2024. DOI: 10.1093/rheumatology/keae392.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.